Genetic Variations in the Human Angiotensin-ConvertingEnzyme 2 and Susceptibility to Coronavirus Disease-19

Talebi, Taravat; Masoumi, Tannaz; Heshmatzad, Katayoun; Hesami, Mahshid; Maleki, Majid; Kalayinia, Samira

doi:https://doi.org/10.1155/2023/2593199

Genetics Research

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Research Article | Open Access

Volume 2023 | Article ID 2593199 | https://doi.org/10.1155/2023/2593199

Genetic Variations in the Human Angiotensin-ConvertingEnzyme 2 and Susceptibility to Coronavirus Disease-19

Taravat Talebi,¹Tannaz Masoumi,¹Katayoun Heshmatzad,¹Mahshid Hesami,¹Majid Maleki,²and Samira Kalayinia²

Academic Editor: Xiaoye Jin

Received25 Jan 2023

Revised06 Nov 2023

Accepted20 Nov 2023

Published29 Nov 2023

Abstract

Background. Health and economies are both affected by the coronavirus disease-19 (COVID-19) global pandemic. Angiotensin-converting enzyme 2 (ACE2) is a polymorphic enzyme that is a part of the renin-angiotensin system, and it plays a crucial role in viral entry. Previous investigations and studies revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ACE2 have a considerable association. Recently, ACE2 variants have been described in human populations in association with cardiovascular and pulmonary conditions. In this study, genetic susceptibility to COVID-19 in different populations was investigated. Methods and Results. We evaluated the identified variants based on the predictive performance of 5 deleteriousness-scoring methods and the 2015 American College of Medical Genetics and Genomics (ACMG) guidelines. The results indicated 299 variants within the ACE2 gene. The variants were analyzed by different in-silico analysis tools to assess their functional effects. Ultimately, 5 more deleterious variants were found in the ACE2 gene. Conclusions. Collecting more information about the variations in binding affinity between SARS-CoV-2 and host-cell receptors due to ACE2 variants leads to progress in treatment strategies for COVID-19. The evidence accumulated in this study showed that ACE2 variants in different populations may be associated with the genetic susceptibility, symptoms, and outcome of SARS-CoV-2 infection.

1. Introduction

Coronavirus disease-19 (COVID-19) with first emergence in Wuhan, China, in December 2019 [1, 2] is the consequence of infection with a novel coronavirus naming severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recognized as the cause of this new infectious respiratory disease. The World Health Organization [3] on March 2, 2020, denoted this infection as a pandemic [4]. Fever, cough, vomiting, diarrhea, and other symptoms are common among patients with COVID-19. Some cases might develop acute respiratory distress syndrome [5], severe pneumonia, multiple organ failure, and even death [6, 7]. The key characteristic laboratory findings include increased C-reactive protein level, aspartate aminotransferase, lymphopenia, and lactate dehydrogenase [8]. Most COVID-19 affected patients manifest mild symptoms or are asymptomatic [9]. Moreover, susceptibility to COVID-19 varies among age groups, with older individuals being more vulnerable than children [10, 11]. Intensive care unit treatment or hospital admission is required in 10–20% of patients affected with severe disease [12]. Older age, high body mass index, the male sex, and underlying comorbidities such as cardiovascular disease, hypertension, obesity, diabetes, and chronic respiratory disease are risk factors for unfavorable outcomes [13].

The main host-cell receptor of the spike glycoprotein (S) of SARS-CoV-2 is angiotensin-converting enzyme 2 [14]. This receptor plays a vital role in virus entry into the cell and its infection [15, 16]. Li et al. showed that specific residues in the human ACE2 (hACE2) receptor are necessary for binding with the pathogen [17]. ACE2 is an important component of the renin-angiotensin system (RAS) [18, 19], which regulates cardiovascular homeostasis, blood pressure, blood volume, and systemic vascular resistance [20, 21]. ACE2 is the main enzyme responsible for converting angiotensin II into angiotensin I [1–7]. The imbalance of the RAS caused by the binding of SARS-CoV-2 to ACE2 is likely to play a role in COVID-19 pathogenesis [22]. Furthermore, ACE2 is associated with cardiovascular disease, kidney disease, hypertension, stroke, and dyslipidemia [23–26]. In the severe acute respiratory syndrome (SARS) outbreak in 2002–2003, which was caused by SARS-CoV, ACE2 played the same role as it plays in SARS-CoV-2 infection [27]. The transmembrane protease serine 2 (TMPRSS2) leads to the cleavage of the C-terminal segment of ACE2 and results in the S protein-driven viral entry [28, 29]. Mutant S proteins can detect host receptors within species [30]. The S protein has 2 subunits: the S1 subunit contains the receptor-binding domain, which targets receptors in the host cells, and the S2 subunit, which regulates membrane fusion between the host cells and the virus [31]. After binding to the ACE2 receptor, the S protein of SARS-CoV-2 is cleaved by the TMPRSS2 protease at the S1/S2 and S2 sites, leading to the activation of the S2 domain and the membrane fusion of the viral and host membranes (Figure 1(a)) [32]. The abundance of ACE2 receptors in any organs of the body, including the brain, heart, kidney, nasopharynx, lymph nodes, small intestine, colon, stomach, thymus, skin, spleen, bone marrow, liver, blood vessels, and oral and nasal mucosa, renders them susceptible to infection by SARS-CoV-2 [10, 33]. Previous in vitro studies have indicated that there exists a positive robust correlation between SARS-CoV infection and ACE2 expression [34, 35]. The levels of ACE2 expression in different tissues are shown in Figure 1(b). ACE2 is highly expressed in lung alveolar epithelial cells leading to considerable severe lung damage and therefore ARDS acute lung damage and pneumonia as the consequence [36]. The secondary and dimerization structures of the ACE2 protein are shown in Figures 2(a) and 2(b), respectively. The crystal structure of the ACE2 receptor is illustrated in Figure 2(c). The binding strength of ACE2 with SARS-CoV-2 is weaker than that with SARS-CoV, and it is regarded as high as the threshold necessary for the infection of the virus. The S protein is a trimeric glycoprotein expressed in the surface of SARS-CoV-2 virion, which regulates recognition of receptor throughout its membrane fusion and receptor-binding domain [37, 38].

(a)

(b)

Figure 1

(a) The image illustrates the intracellular interactions between angiotensin-converting enzyme 2 and its ligand severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). (b) The image shows ACE2 expression in 15 primates and 16 tissues. The level for significantly expressed genes is color-coded in 8 equally sized bins (light-to-dark green). Light gray is for weak not-accurately measured expression (2 to 8 reads above the intergenic background), while dark gray is for no expression or no sequence conservation (0 read in the gene). The plot on the right shows the distribution of the measured expression values in all tissues for all genes (blue) and for this gene in magic index = log2 (1000 sFPKM). HUM: human, CHP: chimpanzee, PTM: pig-tailed Macaque, JMI: Japanese macaque, RMI: rhesus macaque Indian, RMC: rhesus macaque Chinese, CMM: cynomolgus macaque Mauritian, CMC: cynomolgus macaque Chinese, BAB: olive baboon, SMY: sooty mangabey, MST: common marmoset, SQM: squirrel monkey, OWL: owl monkey, MLM: mouse Lemur, RTL: ring-tailed lemur. This information was obtained from the AceView database (https://www.ncbi.nlm.nih.gov/ieb/research/acembly/).

(a)

(b)

(c)

Figure 2

(a) The image depicts the secondary structure of the angiotensin-converting enzyme 2 protein. (b) The image illustrates the dimerization structure of the ACE2 protein with SWISS-MODEL (https://swissmodel.expasy.org/) ID Q9BYF1. ACE2 dimerizes via 2 domains: peptidase-M2 and collectrin, which are shown in color. (c) The image demonstrates the crystal structure of ACE2 with PDB (https://www.rcsb.org/) ID 1R42. The main functional domains of ACE2 that interact with SARS-CoV-2 are illustrated in the box.

Previous investigations have revealed that the SARS-CoV-2 protein binds to hACE2 through Phe486, Leu455, Ala501, Tyr505, and Gln493. The 31, 41, 82, and 353–357 residues in the ACE2 receptor are important for its interaction with the S protein of SARS-CoV-2 [17]. Recent clinical studies have demonstrated that male and female patients with COVID-19 exhibit significant differences in incidence and mortality rates. COVID-19 is associated with underlying conditions such as cardiovascular disease and cancer, as well as in specific patients with hypertension consuming antihypertensive medicines [39]. Genetic variations in the ACE2 gene (Online Mendelian Inheritance in Man (OMIM): 300335) play a critical role in the susceptibility, symptoms, and outcome of SARS-CoV-2 infection in various populations [40]. Some ACE2 polymorphisms may decrease the association between ACE2 and the S protein of SARS-CoV [16]. This suggests that an investigation of the functional ACE2 polymorphisms could promote personalized treatment strategies and precision medicine for COVID-19.

The reported variants of concern (VOCs) included B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron) that have mutations in the receptor-binding domain (RBD) and the N-terminal domain (NTD) of the spike protein [41]. These variants lead to increased virulence and transmissibility, reduced neutralization by antibodies, and reduced efficacy of the treatment or vaccination [41]. The development of drugs that target the spike protein is an appropriate therapeutic strategy, which causes an alteration in binding to the ACE2 receptor [42]. Antiviral drugs, monoclonal antibodies against SARS-CoV-2, anti-inflammatory drugs, and immunomodulatory agents are available as therapeutic strategies [43].

The study aimed to search for the most deleterious variants in the ACE2 gene associated with COVID-19 and the pathogenesis of the identified variants has been evaluated in silico. We highlighted that the ACE2 gene variants could guide personalized treatments. ACE2 polymorphisms could associate with various genetic susceptibility to COVID-19 and treatment outcomes in different ethnic groups. The limitations of this study included that the genomic data in general populations have been examined and the identified ACE2 variants need to be evaluated in a case-control study. Also, further studies should be done in the future to evaluate the impact of these variants.

2. Materials and Methods

2.1. Search Strategy and Data Extraction

In the present study, genetic susceptibility to COVID-19 was investigated by evaluating the variants of the ACE2 gene. The inclusion criteria for variants selection was the variants of ACE2 which are related to COVID-19.

The combination of the following keywords ACE2 and COVID-19, ACE2 variants, and ACE2 [title/abstract] was used in searching PubMed and Google Scholar. Totally, 64 articles were collected, and after duplicate removal, 22 articles remained in which the variants were collected from these related articles. Duplicate publications and studies with overlapping or insufficient data were excluded. The variants were also collected from the Human Gene Mutation Database (HGMD) (https://www.hgmd.cf.ac.uk/ac/index.php) and ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).

The Exome Aggregation Consortium (ExAC: https://exac.broadinstitute.org), the 1000 Genomes Project (KGP) (https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/), the Exome Sequencing Project (https://evs.gs.washington.edu/EVS/), the Genome Aggregation Database (gnomAD v3) (https://gnomad.broadinstitute.org/), Iranome (https://www.iranome.ir/), and the Greater Middle East (GME) Variome Project (https://igm.ucsd.edu/gme/) were used to obtain variants’ frequency.

2.2. Variants Evaluation

It seems that most of the ACE2 variants have not been functionally characterized. We evaluated the identified variants based on the 5 prediction tools score according to the threshold value, including Combined Annotation Dependent Depletion (CADD) (https://cadd.gs.washington.edu/home) [44], Sorting Intolerant from Tolerant (SIFT) (https://sift.bii.a-star.edu.sg/) [45], Polymorphism Phenotyping v2 (PolyPhen-2) (https://genetics.bwh.harvard.edu/pph2/) [46], Protein Variation Effect Analyzer (PROVEAN) (https://provean.jcvi.org/index.php) [47], and Mutation Taster (https://www.mutationtaster.org/) [48]. CADD is the most important prediction tool among all bioinformatics software that was used in our manuscript, and the highest CADD Phred for variants evaluation was considered (Phred ≤ 20). Other prediction tools (SIFT, PolyPhen-2, PROVEAN, and MutationTaster) just were explained as descriptive in the range (SIFT: score ≤ 0.05: deleterious, score > 0.05: tolerable; Polyphen-2: score = 0–0.15: benign, score = 0.15–0.85: possibly damaging, score = 0.85–1: probably damaging; PROVEAN: score ≤ −2.5: deleterious, score > −2.5: neutral). We found the variants in the ACE2 genes that have strong criteria for pathogenesis, i.e., described as a pathogen variant in at least 3 tools. Nomenclature for variants was also confirmed according to the recommendations of the Human Genetic Variation Society (HGVS) (https://varnomen.hgvs.org/). We found the potentially deleterious variants in the ACE2 gene based on the 2015 American College of Medical Genetics and Genomics (ACMG) guidelines for the interpretation of sequence variants [5].

3. Results

3.1. Genetic Analysis of hACE2

The variations in the ACE2 gene are probably important not only in modulating the host susceptibility to SARS-CoV-2 infection but also in determining the severity of local and systemic tissue damage [49]. In the present study, we collected variant datasets from 6 databases: ExAC, 1KGP, ESP6500, gnomAD, Iranome, and GME. Given that any frequency databases which were used in our study are due to global standards and their population study and methods were different, the minor allele frequency (MAF) of any databases is different. Indeed, we used this information to identify variants with MAF below some specified threshold, which likely relate to disease. ExAC has collected, harmonized, and released exome sequence data from 60706 individuals. 1000G is about common genetic variants with frequencies of at least 1% in the populations studied. ESP6500 is a database of genes and mechanisms that contribute to blood, lung, and heart disorders through NGS data in various populations. gnomAD is a coalition of investigators seeking to aggregate and harmonize exome and genome sequencing data from a variety of large-scale sequencing projects and to make summary data available for the wider scientific community. Iranome is a catalog of genomic variations in the Iranian population. GME generated a coding base reference for the countries found in the Greater Middle East. As we know, the genetic variations of each population are different from the other. Our results revealed 299 variants in the ACE2 gene. A list of the identified variants in the ACE2 gene is summarized in Table 1. The majority of the ACE2 gene variants have yet to be identified functionally. To obtain information about the possibility of the deleterious effects of the identified variants, we evaluated the variants using the in-silico prediction of their functional effects. Ultimately, we identified the most deleterious variants in the ACE2 gene based on prediction tools (Figure 3, Table 2).

3.2. Variants of the ACE2 Gene

Cao et al. explored the allele frequency distribution of 1700 ACE2 gene variants using China Metabolic Analytics and 1K1000 Genomes [50]. Twenty-five variants located within the ACE2 gene were collected and cataloged in the Leiden Open Variation Database [14]. Single-nucleotide variations (SNVs) with a low allele frequency appear to be more deleterious than SNVs with a high allele frequency according to some scoring methods [51]. According to a study by Hou et al., 39% and 54% of deleterious variants in the ACE2 gene are carried by African/African-American and Non-Finnish European populations, respectively. Specifically, 2–10% of deleterious variants in this gene occur in Latino/Admixed American, East Asian, Finnish, and South Asian populations, while Amish and Ashkenazi Jewish populations do not carry deleterious variants in the ACE2 coding regions [40]. The variants p.Met383Thr, p.Asp427Tyr, and p.Arg514Gly are carried by African/African-American populations, with an allele frequency of 0.003%, 0.01%, and 0.003%, respectively. Additionally, the p.Pro389His variant, with an allele frequency of 0.015%, is carried by Latino/Admixed American populations only [40]. According to a previous study, several ACE2 variants and alterations in amino acid residues in ACE2 could affect the association between the ACE2 receptor and the S protein in SARS-CoV, leading to the conversion of ACE2 into an efficient/inefficient receptor [17]. Fujikura and Uesaka identified 8 SNVs—namely p.Ser19Pro, p.Thr27Ala, p.Glu35Lys, p.Glu35Asp, p.Glu37Lys, p.Met82Ile, p.Glu329Gly, and p.Asp355Asn—in the ACE2 gene in the direct contact residues of the S protein of SARS-CoV/SARS-CoV-2 and hACE2 [51]. Residues Arg708/710/716, located in the dimeric interface of the ACE2 receptor, are a vital component for cleavage by TMPRSS2. This process is required to strengthen the entry of the virus into the host cells [29]. Notably, the variants p.Arg708Trp, p.Arg710Cys, p. Arg710His, and p.Arg716Cys with an allele frequency of 0.01∼0.006% are carried by European populations. East Asian and Latino/Admixed American populations only carry the variants p.Arg708Trp and p.Arg710His, which have an allele frequency of 0.04% and 0.01%, respectively [40]. Several variants, including p.Met383Thr, p.Pro389His, and p.Asp427Tyr, inhibited the interaction between the ACE2 receptor and the S protein of SARS-CoV-1 in the SARS outbreak in 2002 [17]. There are natural ACE2 variants that alter the interaction between the virus and the host cells and, as a result, potentially change the susceptibility of the host. In particular, 9 variants—namely, I21V, Q102P, S19P, K26R, E23K, T27A, T92I, N64K, and H378R—were found in the hACE2 gene, which increased viral binding susceptibility, while 17 variants—namely, K31R, N33I, H34R, E35K, E37K, D38V, Y50F, N51S, M62V, K68E, F72V, Y83H, G326E, G352V, D355N, Q388L, and D509Y—were predicted to decrease the binding affinity of the S protein of SARS-CoV-2 and were, thus, considered protective variants [52]. The variants rs73635825 and rs143936283 present a relatively low binding affinity for the S protein of SARS-CoV-2, which may be associated with potential resistance to infection [49]. Information regarding these variants is not available in Iranome. Three variants—namely, p.Lys26Arg, p.Gly211Arg, and p.Asn720Asp—were more frequently expressed in the Italian population than in the Eastern Asian population. These variants are close to the sequence essential for the binding of the S protein of SARS-CoV-2. The presence of these variants may explain the high mortality rate in Italy compared with China [49, 53]. ACE2 gene mutation naming Leu584Ala facilitates the SARS-CoV entry into target cells [54]. Cao et al. characterized 32 variants in the ACE2 gene, among which there were 7 hotspot variants—namely, Lys26Arg, Ile486Val, Ala627Val, Asn638Ser, Ser692Pro, Asn720Asp, and Leu731Ile/Phe—in different populations [50]. Benetti et al. concluded that 3 more common missense variants—namely, p.Gly211Arg, p.Lys26Arg, and p.Asn720Asp—could interfere with both protein structure and its stabilization. Furthermore, the two rare variants of p.Pro389His and p.Leu351Val were predicted to interfere with the binding of the SARS-CoV-2 S protein [4]. Based on the findings of the present study, differential variants in the ACE2 gene may clarify various susceptibility and outcomes in different ethnic groups.

4. Discussion

The ACE2 receptor acts as an entry point for the coronavirus [55]. In addition to the strategy of using viral replication inhibitors, another strategy in the treatment option is to block the cellular target of the virus, ACE2 [56]. Certain genomic variants within the ACE2 gene that modulate its function or expression cause variable susceptibility to SARS-CoV-2 infection [20]. Given the possible connection between circulating ACE2 levels and COVID-19 severity, recombinant ACE2 may be a promising treatment option [57]. As a result, tissue-specific ACE2 expression or plasma ACE2 levels are considered 2 important factors in the severity of COVID-19. The effects of antihypertensive therapy by both angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARBs) may lead to increased expression levels of ACE2. Studies have shown that the increased level of soluble ACE2 may act as a competitor to SARS-CoV-2 and may, thus, reduce viral penetration into cells and lung tissue [58, 59]. According to a meta-analysis, ACE-I/ARBs reduced the risk of pneumonia and its mortality [60]. The rs2285666 polymorphism may be a predisposing factor for the comorbidities observed in patients with COVID-19 [61, 62]. The population-based frequency of this single-nucleotide polymorphism (SNP) is significantly higher among the Indian population (∼0.6) than among Europeans (0.2) and East Asians (0.55) [21, 50, 62]. In our study, among the Iranian population, we identified a frequency of 0.2575 for this SNP. The results of another study conducted by Srivastava et al. indicated that the frequency of a synonymous coding region variant, rs35803318, was high among Americans (0.15), followed by Europeans (0.055), Caucasians (0.051), and Central Asians (0.021). In the current study, we also detected a frequency of 0.0325 for this SNP among the Iranian population. It appears that some of the identified variants or the cumulative effect of a few of them cause different susceptibility to the entry of viral cells and have a significant effect on the onset and progression of the disease. Therefore, systematic identification of the genetic determinants of COVID-19 susceptibility and the clinical outcome could further explain the current epidemiologic observations, disease pathophysiology, different susceptibilities, and disease severities in different ethnic groups.

In the present study, we conduct a comprehensive systematic investigation on genetic variations in the human genes associated with the coronavirus. The reason for choosing the ACE2 gene in this study was that variants of this gene may be able to modulate intermolecular interactions with the S protein of SARS-CoV-2 and are associated with altering virulence, pathogenicity, clinical outcome, and COVID-19 susceptibility. In the present study, we provided the dataset of ACE2 variants (Table 1). The ACE2 gene variants may be associated with COVID-19 genetic susceptibility which could guide more personalized and individualized treatments for the COVID-19 pandemic [40]. Since ACE2 gene variants may cause different responses to COVID-19 treatments concerning the components of the RAS system, we recommend case-control studies to investigate the effects of these variants on treatment outcomes. In addition, the testing of the ACE2 gene polymorphisms has been recommended for patients with COVID-19 undergoing clinical trials with ACE-I/ARBs [9]. Worldwide study on the genes linked to life-threatening instances is required despite the development of many licensed vaccinations, the mutation of coronaviruses, and the potential for pandemics. It is also necessary to obtain information on variants for population-appropriate vaccines against SARS-CoV-2 infection.

This study aimed to search for the most deleterious variants associated with COVID-19, and the pathogenesis of the identified variants has been investigated in silico. We selected the variants with the highest CADD score and were considered as deleterious, damaging, and disease causing in at least three prediction tools. Also, the MAF of the selected variants in the frequency databases was very low, and these variants can be very important in the incidence of the disease (Figure 3, Table 2). Finally, we found the five variants caused the changes in amino acid residues of the extracellular domain of the ACE2 receptor (residues 18–740) that includes a zinc-binding site (residues 374–378, His-Glu-Met-Gly-His). The mutated residues are located in the extracellular domain which plays an important role in the main activity of the ACE2 protein, and these variants can consequently disturb its normal function. The S protein of SARS-CoV-2 is identified by the extracellular peptidase domain of the ACE2 receptor and leads to the binding of the virus to the host cell. Probably, each of these five deleterious variants mentioned in this study caused a disturbance in the structure of the ACE2 receptor, which may be effective in the incidence of this disease. The c.1129G > T variant in the ACE2 gene caused the Gly377Gln substitution within the extracellular domain of the receptor. This residue is located in the zinc-binding site (positions 374–378) that is involved in binding. The E37K variant is in the direct contact residues of hACE2 and the S protein that play a role in the entry of the virus into the host cells. The initial attachment of the S protein to the receptor has caused the exposure of the most important amino acids for binding (residues 22–57). The main functional domains of the ACE2 receptor that interact with SARS-CoV-2 are illustrated in Figure 2(c). The c.109G > A variant in the ACE2 gene caused the Glu37Lys substitution within the main functional domains of ACE2 (residues 30–41). Also, amino acid glycine at position 37 is the main residue at the interface.

According to this study, the five deleterious variants in the ACE2 gene may clarify various susceptibility and outcomes in different ethnic groups. These ACE2 variants and alterations in amino acid residues in the receptor alter the interaction between the virus and host cells, resulting in altering the host susceptibility. Therefore, we recommend further research to identify the effect of the most pathogenic variants on the binding affinity. Also, the identified pathogenic variants in the ACE2 gene may affect the clinical efficacy of drugs for COVID-19, which is better investigated. We suggest that the frequency of these deleterious variants in different populations is investigated in the future so that the necessary preparations for the disease are considered in populations carrying these variants.

The tissue-specific ACE2 expression and plasma ACE2 levels, and density of ACE2 receptors are key factors of the difference in the severity and incidence of the disease in various countries. Also, the levels of ACE2 expression vary in different populations and various human tissues (Figure 1(b)). SNPs affect gene expression and lead to a change in the outcome of the disease. We recommend that these factors be investigated in individuals with these variants in different populations that could promote personalized treatment strategies and precision medicine for COVID-19. Such studies may affect accurate medical interventions and the design of specific diagnostic and therapeutic methods for coronavirus. The present study can be useful for better understanding interindividual clinical variability, and the severity and susceptibility of this disease in different ethnic groups.

The mechanisms resulting from the functional foods-based treatments included the reduced expression of ACE2 receptors in cells, inhibiting necessary enzymes in SARS-CoV-2, and decreased proinflammatory cytokines that can help the body fight during illness [63]. The mentioned variants that modulate the ACE2 function and expression cause variable susceptibility to SARS-CoV-2 infections. It seems to be beneficial for patients carrying these variants to use the functional foods-based treatments that lead to the reduced expression of ACE2 receptors in the cells. Therefore, we recommend further research to identify the effect of the most pathogenic variants in different populations on the ACE2 tissue expression, plasma ACE2 levels, and binding affinity, leading to improved therapeutic strategies and precision medicine for COVID-19. We suggested that the testing of the polymorphisms and the most pathogenic variants in the ACE2 gene should be considered when determining the type of drugs in patients with more severe symptoms. According to the studies, numerous polymorphisms are associated with high ACE2 tissue expression and higher severity, whereas some polymorphisms are associated with low ACE2 tissue expression and lesser severity. As a result, the treatment outcomes in COVID-19 patients are influenced by the ACE2 variants. The spike protein mutations increased the viral attachment and subsequent entry into host cells. The structural target for available drugs and treatments is the high binding affinity of the spike protein and the receptor. It appears that some of the identified variants and their cumulative effects of them cause different susceptibility to the entry of viral cells and have a significant effect on the used therapeutics and vaccination effectiveness. Given the possibility that treatment-resistant variants may emerge that could lead to destructive and irrecoverable impacts on global health, continuous viral surveillance of new variants should be performed using viral genomic sequencing. Both the virus and receptor variants are two important factors in the susceptibility and severity of this disease. Therefore, we suggest that both factors should be considered to select the proper therapeutic strategy. Despite the production of several approved vaccines, mass vaccination, recommending vaccine boosters, the latest novel therapeutics available, and food-based treatments, the significant progress made so far in stopping the spread of SARS-CoV-2 is threatened by the continued emergence of new variant strains of SARS-CoV-2. It also highlights further investigation on genes associated with life-threatening cases is necessary due to adaptive mutations in the viral genome that can change the pathogenic potential of this virus. The evaluation of pathogenic variants in the ACE2 gene in male and female genders and different populations with the appropriate therapeutic strategies can be effective to prevent infections among populations at risk of SARS-CoV-2 infections resulting from possible viral variants.

5. Conclusions

The detection of SNP genotypes is urgently needed to discover likely genetic risk factors for severe outcomes. The identification of variants may have a significant impact on the variability of the COVID-19 course and may confer precision medicine interventions, treatment individualization and design, and inexpensive and accurate DNA-based tests for the coronavirus. Our genetic analysis of variants in the hACE2 gene suggests that the ACE2 variants may be associated with COVID-19 susceptibility and clinical outcomes.

Data Availability

All the data generated or analyzed during this study are included in this published article. The datasets generated and/or analyzed during the current study are available in the HGMD (https://www.hgmd.cf.ac.uk/ac/index.php), ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), and Google Scholar (https://scholar.google.com/).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

We appreciate the support from the Cardiogenetic Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

References

N. Zhu, D. Zhang, W. Wang et al., “A novel coronavirus from patients with pneumonia in China,” New England Journal of Medicine, vol. 382, no. 8, pp. 727–733, 2019.
View at: Publisher Site | Google Scholar
C. Huang, Y. Wang, X. Li et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The Lancet, vol. 395, no. 10223, pp. 497–506, 2020.
View at: Publisher Site | Google Scholar
C. Wallace, S. J. Newhouse, P. Braund et al., “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia,” The American Journal of Human Genetics, vol. 82, no. 1, pp. 139–149, 2008.
View at: Publisher Site | Google Scholar
E. Benetti, R. Tita, O. Spiga et al., “ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population,” European Journal of Human Genetics, vol. 28, no. 11, pp. 1602–1614, 2020.
View at: Publisher Site | Google Scholar
S. Richards, N. Aziz, S. Bale et al., “Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology,” Genetics in Medicine, vol. 17, no. 5, pp. 405–424, 2015.
View at: Publisher Site | Google Scholar
N. Chen, M. Zhou, X. Dong et al., “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study,” The Lancet, vol. 395, no. 10223, pp. 507–513, 2020.
View at: Publisher Site | Google Scholar
M. Liu, T. Wang, Y. Zhou, Y. Zhao, Y. Zhang, and J. Li, “Potential role of ACE2 in coronavirus disease 2019 (COVID-19) prevention and management,” Journal of translational internal medicine, vol. 8, no. 1, pp. 9–19, 2020.
View at: Publisher Site | Google Scholar
M. A. Lake, “What we know so far: COVID-19 current clinical knowledge and research,” Clinical Medicine, vol. 20, no. 2, pp. 124–127, 2020.
View at: Publisher Site | Google Scholar
H. Zheng and J. J. Cao, “Angiotensin-converting enzyme gene polymorphism and severe lung injury in patients with coronavirus disease 2019,” The American Journal of Pathology, vol. 190, no. 10, pp. 2013–2017, 2020.
View at: Publisher Site | Google Scholar
T. Behl, I. Kaur, S. Bungau et al., “The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions,” Life Sciences, vol. 257, Article ID 118075, 2020.
View at: Publisher Site | Google Scholar
N. Dhochak, T. Singhal, S. Kabra, and R. Lodha, “Pathophysiology of COVID-19: why children fare better than adults?” Indian Journal of Pediatrics, vol. 87, no. 7, pp. 537–546, 2020.
View at: Publisher Site | Google Scholar
A. R. Bourgonje, A. E. Abdulle, W. Timens et al., “Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19),” The Journal of Pathology, vol. 251, no. 3, pp. 228–248, 2020.
View at: Publisher Site | Google Scholar
F. Zhou, T. Yu, R. Du et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” The Lancet, vol. 395, no. 10229, pp. 1054–1062, 2020.
View at: Publisher Site | Google Scholar
Lovd, “Angiotensin i converting enzyme (peptidyl-dipeptidase a) 2,” 2020, https://databases.lovd.nl/shared/genes/ACE2.
View at: Google Scholar
M. Hoffmann, H. Kleine-Weber, S. Schroeder et al., “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor,” Cell, vol. 181, no. 2, pp. 271–280, 2020.
View at: Publisher Site | Google Scholar
R. Lu, X. Zhao, J. Li et al., “Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding,” The Lancet, vol. 395, no. 10224, pp. 565–574, 2020.
View at: Publisher Site | Google Scholar
W. Li, C. Zhang, J. Sui et al., “Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2,” European Molecular Biology Organization Journal, vol. 24, no. 8, pp. 1634–1643, 2005.
View at: Publisher Site | Google Scholar
M. Donoghue, F. Hsieh, E. Baronas et al., “A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9,” Circulation Research, vol. 87, no. 5, pp. 1–9, 2000.
View at: Publisher Site | Google Scholar
S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner, “A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase,” Journal of Biological Chemistry, vol. 275, no. 43, pp. 33238–33243, 2000.
View at: Publisher Site | Google Scholar
A. Srivastava, A. Bandopadhyay, D. Das et al., “Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India,” Frontiers in Genetics, vol. 11, Article ID 564741, 2020.
View at: Publisher Site | Google Scholar
A. Srivastava, R. K. Pandey, P. P. Singh et al., “Most frequent South Asian haplotypes of ACE2 share identity by descent with East Eurasian populations,” PLoS One, vol. 15, no. 9, Article ID e0238255, 2020.
View at: Publisher Site | Google Scholar
L. B. Costa, L. G. Perez, V. A. Palmeira et al., “Insights on SARS-CoV-2 molecular interactions with the renin-angiotensin system,” Frontiers in Cell and Developmental Biology, vol. 8, Article ID 559841, 2020.
View at: Publisher Site | Google Scholar
Q. Zhang, M. Cong, N. Wang et al., “Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case–control study,” Medicine, vol. 97, no. 42, Article ID e12917, 2018.
View at: Publisher Site | Google Scholar
M. Wang, W. Zhang, Y. Zhou, and X. Zhou, “Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting,” Experimental and Therapeutic Medicine, vol. 7, no. 6, pp. 1721–1727, 2014.
View at: Publisher Site | Google Scholar
X. Wu, B. Zhu, S. Zou, and J. Shi, “The association between ACE2 gene polymorphism and the stroke recurrence in Chinese population,” Journal of Stroke and Cerebrovascular Diseases, vol. 27, no. 10, pp. 2770–2780, 2018.
View at: Publisher Site | Google Scholar
Y. Pan, T. Wang, Y. Li et al., “Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China,” Lipids in Health and Disease, vol. 17, pp. 241–249, 2018.
View at: Publisher Site | Google Scholar
M. Chaudhary, “COVID-19 susceptibility: potential of ACE2 polymorphisms,” Egyptian Journal of Medical Human Genetics, vol. 21, pp. 54–58, 2020.
View at: Publisher Site | Google Scholar
A. Shulla, T. Heald-Sargent, G. Subramanya, J. Zhao, S. Perlman, and T. Gallagher, “A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry,” Journal of Virology, vol. 85, no. 2, pp. 873–882, 2011.
View at: Publisher Site | Google Scholar
A. Heurich, H. Hofmann-Winkler, S. Gierer, T. Liepold, O. Jahn, and S. Pöhlmann, “TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein,” Journal of Virology, vol. 88, no. 2, pp. 1293–1307, 2014.
View at: Publisher Site | Google Scholar
H. Nemati, M. Ramezani, F. Najafi, B. Sayad, M. Nazeri, and M. Sadeghi, “Evaluation of angiotensin-converting enzyme 2 (Ace2) in covid-19: a systematic review on all types of studies for epidemiologic, diagnostic, and therapeutic purposes,” Open Access Macedonian Journal of Medical Sciences, vol. 8, no. T1, pp. 84–91, 2020.
View at: Publisher Site | Google Scholar
F. Li, W. Li, M. Farzan, and S. C. Harrison, “Structure of SARS coronavirus spike receptor-binding domain complexed with receptor,” Science, vol. 309, no. 5742, pp. 1864–1868, 2005.
View at: Publisher Site | Google Scholar
E. Hartenian, D. Nandakumar, A. Lari, M. Ly, J. M. Tucker, and B. A. Glaunsinger, “The molecular virology of coronaviruses,” Journal of Biological Chemistry, vol. 295, no. 37, pp. 12910–12934, 2020.
View at: Publisher Site | Google Scholar
I. Hamming, W. Timens, M. Bulthuis, A. Lely, G. V. Navis, and H. van Goor, “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis,” The Journal of Pathology, vol. 203, no. 2, pp. 631–637, 2004.
View at: Publisher Site | Google Scholar
H. Hofmann, M. Geier, A. Marzi et al., “Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor,” Biochemical and Biophysical Research Communications, vol. 319, no. 4, pp. 1216–1221, 2004.
View at: Publisher Site | Google Scholar
Y. Imai, K. Kuba, and J. M. Penninger, “The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice,” Experimental Physiology, vol. 93, no. 5, pp. 543–548, 2008.
View at: Publisher Site | Google Scholar
H. Zhang and A. Baker, “Recombinant human ACE2: acing out angiotensin II in ARDS therapy,” Critical Care, vol. 21, no. 1, p. 305, 2017.
View at: Publisher Site | Google Scholar
D. Wrapp, N. Wang, K. S. Corbett et al., “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,” Science, vol. 367, no. 6483, pp. 1260–1263, 2020.
View at: Publisher Site | Google Scholar
R. Yan, Y. Zhang, Y. Li, L. Xia, Y. Guo, and Q. Zhou, “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2,” Science, vol. 367, no. 6485, pp. 1444–1448, 2020.
View at: Publisher Site | Google Scholar
T. Guo, Y. Fan, M. Chen et al., “Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19),” Journal of the American Medical Association Cardiology, vol. 5, no. 7, pp. 811–818, 2020.
View at: Publisher Site | Google Scholar
Y. Hou, J. Zhao, W. Martin et al., “New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis,” BMC Medicine, vol. 18, pp. 216–218, 2020.
View at: Publisher Site | Google Scholar
A. Aleem, A. S. Ab, and A. K. Slenker, Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19), Springer, Berlin, Germany, 2021.
D. D. Singh, A. Sharma, H.-J. Lee, and D. K. Yadav, “SARS-CoV-2: recent variants and clinical efficacy of antibody-based therapy,” Frontiers in Cellular and Infection Microbiology, vol. 12, Article ID 839170, 2022.
View at: Publisher Site | Google Scholar
C. M. Coopersmith, M. Antonelli, S. R. Bauer et al., “The surviving sepsis campaign: research priorities for coronavirus disease 2019 in critical illness,” Critical Care Medicine, vol. 49, no. 4, pp. 598–622, 2021.
View at: Publisher Site | Google Scholar
M. Kircher, D. M. Witten, P. Jain, B. J. O'roak, G. M. Cooper, and J. Shendure, “A general framework for estimating the relative pathogenicity of human genetic variants,” Nature Genetics, vol. 46, no. 3, pp. 310–315, 2014.
View at: Publisher Site | Google Scholar
P. Kumar, S. Henikoff, and P. C. Ng, “Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm,” Nature Protocols, vol. 4, no. 7, pp. 1073–1081, 2009.
View at: Publisher Site | Google Scholar
I. Adzhubei, D. M. Jordan, and S. R. Sunyaev, “Predicting functional effect of human missense mutations using PolyPhen-2,” Current protocols in human genetics, vol. 7, no. 1, pp. 7–20, 2013.
View at: Publisher Site | Google Scholar
Y. Choi, G. E. Sims, S. Murphy, J. R. Miller, and A. P. Chan, Predicting The Functional Effect of Amino Acid Substitutions and Indels, Public Library of Science San Francisco, San Francisco, CA, USA, 2012.
J. M. Schwarz, D. N. Cooper, M. Schuelke, and D. Seelow, “MutationTaster2: mutation prediction for the deep-sequencing age,” Nature Methods, vol. 11, no. 4, pp. 361-362, 2014.
View at: Publisher Site | Google Scholar
G. Lippi, C. J. Lavie, B. M. Henry, and F. Sanchis-Gomar, “Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?” Clinical Chemistry and Laboratory Medicine, vol. 58, no. 9, 2020.
View at: Google Scholar
Y. Cao, L. Li, Z. Feng et al., “Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations,” Cell discovery, vol. 6, pp. 11–14, 2020.
View at: Publisher Site | Google Scholar
K. Fujikura and K. Uesaka, “Genetic variations in the human severe acute respiratory syndrome coronavirus receptor ACE2 and serine protease TMPRSS2,” Journal of Clinical Pathology, vol. 74, no. 5, pp. 307–313, 2020.
View at: Publisher Site | Google Scholar
E. W. Stawiski, D. Diwanji, K. Suryamohan et al., “Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility,” 2020, https://www.biorxiv.org/content/10.1101/2020.04.07.024752v1.
View at: Google Scholar
G. Lippi, C. Mattiuzzi, F. Sanchis-Gomar, and B. M. Henry, “Clinical and demographic characteristics of patients dying from COVID-19 in Italy vs China,” Journal of Medical Virology, vol. 92, no. 10, pp. 1759-1760, 2020.
View at: Publisher Site | Google Scholar
F. Xiao, J. Zimpelmann, S. Agaybi, S. B. Gurley, L. Puente, and K. D. Burns, “Characterization of angiotensin-converting enzyme 2 ectodomain shedding from mouse proximal tubular cells,” PLoS One, vol. 9, no. 1, Article ID e85958, 2014.
View at: Publisher Site | Google Scholar
W. Li, M. J. Moore, N. Vasilieva et al., “Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus,” Nature, vol. 426, no. 6965, pp. 450–454, 2003.
View at: Publisher Site | Google Scholar
A. C. Walls, Y.-J. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler, “Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein,” Cell, vol. 181, no. 2, pp. 281–292, 2020.
View at: Publisher Site | Google Scholar
E. Ciaglia, C. Vecchione, and A. A. Puca, “COVID-19 infection and circulating ACE2 levels: protective role in women and children,” Frontiers in pediatrics, vol. 8, p. 206, 2020.
View at: Publisher Site | Google Scholar
B. Williams, G. Mancia, W. Spiering et al., “2018 practice guidelines for the management of arterial hypertension of the European society of cardiology and the European society of hypertension,” Blood Pressure, vol. 27, no. 6, pp. 314–340, 2018.
View at: Publisher Site | Google Scholar
D. Batlle, J. Wysocki, and K. Satchell, “Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?” Clinical Science, vol. 134, no. 5, pp. 543–545, 2020.
View at: Publisher Site | Google Scholar
D. Caldeira, J. Alarcão, A. Vaz-Carneiro, and J. Costa, “Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis,” British Medical Journal, vol. 345, no. 1, Article ID e4260, 2012.
View at: Publisher Site | Google Scholar
J. Chaoxin, S. Daili, H. Yanxin, G. Ruwei, W. Chenlong, and T. Yaobin, “The influence of angiotensin-converting enzyme 2 gene polymorphisms on type 2 diabetes mellitus and coronary heart disease,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 19, pp. 2654–2659, 2013.
View at: Google Scholar
R. Asselta, E. M. Paraboschi, A. Mantovani et al., “ACE2 and TMPRSS2 Variants and Expression as Candidates to Sex and Country Differences in COVID-19 Severity in Italy Orthopaedic Guidelines for the COVID-19 Post-Outbreak Period: Experience from Wuhan, People's Republic of China,” Aging (Albany, NY), 2020.
View at: Google Scholar
M. Farzana, S. Shahriar, F. R. Jeba et al., “Functional food: complementary to fight against COVID-19,” Beni-Suef University journal of basic and applied sciences, vol. 11, no. 1, p. 33, 2022.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2023 Taravat Talebi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

242

Downloads

235

Citations